ClinicalTrials.gg
RecruitingNCT07449195Updated May 13, 2026

A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors

An interventional study of Intalight Dream OCT and Heidelberg Spectralis OCT in Ocular Tumor, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Eye Neoplasms with a site in United States — 4 open to participants now, 8 under way, 1 of them phase 3. Eye Neoplasms · United States.

Planned enrollment
6th of 15
60 · median 40
Started
2026
the only one that year
No phase
2 of 22
1 open now
Registered
22nd of 22
by date
Lead sponsor
2 of 22
Memorial Sloan Kettering Cancer Center

Among the 22 studies in Eye Neoplasms with a site in United States, this one is the 6th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 2 with no phase, and was the 22nd registered.

Eye Neoplasms

32 studies on the registry are indexed under Eye Neoplasms; 4 are open to participants now.

Browse Eye Neoplasms studies →

Open to participants now

4 of the 22 studies in Eye Neoplasms with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Eye Neoplasms studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Eye Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare two devices used for optical coherence tomography (OCT). OCT is a noninvasive imaging (scanning) method that uses reflected light to create pictures of the back of the eye, and doctors can use OCT to detect and monitor different types of cancer

03

Conditions studied

  • Ocular Tumor

Browse trials for

Keywords

  • Ocular Tumors
  • 25-314
  • Memorial Sloan Kettering Cancer Center
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • At least 1 eye that has an intraocular or ocular surface tumor.
  • The presence of a natural crystalline lens or intraocular lens.
  • Pupils that can dilate up to at least 3 mm in the study eyes.
  • The absence of opaque natural crystalline lenses or the presence of any ocular disease that prevents the view of the retina for imaging.
  • Patients must be able to fixate on the imaging target.
  • Patients must be able to sit still for a period of time (approximately 2 minutes).

Exclusion criteria

Exclusion Criteria:

  • Does not meet ALL of the above conditions
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Participants with Ocular Tumor

    Participants will have at least 1 eye that has an intraocular or ocular surface tumor.

    Diagnostic Test: Intalight Dream OCT · Diagnostic Test: Heidelberg Spectralis OCT

Interventions

  • Diagnostic testIntalight Dream OCT

    This is a next-generation swept-source device that has a faster imaging speed and higher sensitivity than the previous generation of frequency-domain OCT devices, which serve as the current standard of care devices.

  • Diagnostic testHeidelberg Spectralis OCT

    This is the standard of care for optical imaging.

06

What researchers measure

Primary outcomes

  1. Image quality for participants

    Evaluated by next-generation swept-source OCT versus standard OCT for imaging of the eye and any relevant ocular tumors.

    Time frame: Up to 1 year

  2. Field of view for participants

    Evaluated by next-generation swept-source OCT versus standard OCT for imaging of the eye and any relevant ocular tumors.

    Time frame: Up to 1 year

07

Study locations

7 of 7 sites recruiting
  • Memorial Sloan Kettering at Basking Ridge (Consent Only)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Jasmine Francis, MD · Contact212-639-7266
  • Memorial Sloan Kettering Monmouth (Consent only)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Jasmine Francis, MD · Contact212-639-7266
  • Memorial Sloan Kettering Bergen (Consent Only)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Jasmine Francis, MD · Contact212-639-7266
  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only)
    Commack, New York 11725, United States
    Recruiting
    • Jasmine Francis, MD · Contact212-639-7266
  • Memorial Sloan Kettering Westchester (Consent Only)
    Harrison, New York 10604, United States
    Recruiting
    • Jasmine Francis, MD · Contact212-639-7266
  • Memorial Sloan Kettering Cancer Center (All Protocol Activites)
    New York, New York 10065, United States
    Recruiting
    • Jasmine Francis, MD · Contact212-639-7266
  • Memorial Sloan Kettering Cancer Center @ Nassau (Consent only)
    Uniondale, New York 11553, United States
    Recruiting
    • Jasmine Francis, MD · Contact212-639-7266
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Feb 2028, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 4, 2026
StartActual
Feb 27, 2026
Primary completionEst.
Feb 27, 2028
CompletionEst.
Feb 27, 2028
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07449195
Collaborators
Intalight, Inc
Responsible party
Sponsor
First posted
Mar 4, 2026
Start date
Feb 27, 2026
Primary completion
Feb 27, 2028 (estimated)
Completion
Feb 27, 2028 (estimated)
Last update
May 13, 2026

Study contacts

Jasmine Francis, MD
Contact
francij1@mskcc.org
212-639-7266
David Abramson, MD
Contact
abramsod@mskcc.org
212-639-7232
Jasmine Francis, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion